Brief: Nymox says prostate cancer clinical trial will complete prospective 18 month post-treatment assessments
08/10/2015 16:00
Oct 8 (Reuters) - Nymox Pharmaceutical Corp NYMX.O : * Announces prostate cancer clinical trial will complete prospective 18 month post-treatment assessments * Says from this 18 month study are expected to be reported this quarter, after the 18 month data has been analyzed * Source text for Eikon ID:nGNXMCVHVa * Further company coverage NYMX.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba